^
Association details:
Biomarker:PD-L1 elevation
Cancer:Non-Hodgkin’s Lymphoma
Regimen:L/P-VIPD (cisplatin + dexamethasone injection + etoposide IV + ifosfamide + Kidrolase (L-asparaginase) + Oncaspar liquid (pegaspargase))
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type

Published date:
12/01/2020
Excerpt:
L/P-VIPD was used to treat 67 patients….The prognostic significance of plasma exoPD-L1 was evaluated in our cohort. Patients with a high pretreatment plasma exoPD-L1 level had worse 5-year PFS (35.7% vs. 86.1%, P=0.007) and OS (56.0% vs. 88.1%, P=0.012) than those with a low pretreatment exoPD-L1 level (Figure 3D, ​,3E3E)....For stage I patients (n=47), subgroup analysis demonstrated that a high sPD-L1 level was an adverse factor affecting the survival outcome....In our study, univariate analysis demonstrated that the baseline SUVmax (P=0.002), plasma exoPD-L1 (P=0.007), sPD-L1 (P=0.003) and an L-asp/peg-containing regimen (P=0.031) were significant factors affecting PFS.
DOI:
10(12): 4498–4512